Globant S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 9, 2020, reports on a significant capital raising event by Globant S.A., a foreign private issuer. The filing details an underwriting agreement entered into on June 4, 2020, with J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC as representatives.
Key Financial Metrics and Transaction Details
- Offering Size: 2,000,000 common shares initially, plus an additional 300,000 shares upon exercise of the underwriters' option.
- Total Shares Sold: 2,300,000 common shares (nominal value $1.20 per share).
- Offering Price: $135.00 per common share.
- Estimated Gross Proceeds: Approximately $310.5 million (2,300,000 shares x $135.00).
- Underwriters: J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period, as this document focuses solely on the equity offering.
Material Changes
The primary material change is the increase in the Company's outstanding common shares and the influx of capital from the public offering. The underwriters exercised their option to purchase the additional 300,000 shares on June 5, 2020.
Guidance, Outlook, and Risks
This filing does not contain management commentary, forward-looking guidance, or specific risk factors related to operations. It serves as a disclosure of the transaction terms and incorporates the Underwriting Agreement and related legal opinions by reference.
Key Facts for Investor Verification
- Verify the final net proceeds to the Company after deducting underwriting discounts and commissions, which are detailed in the attached Underwriting Agreement (Exhibit 1.1).
- Confirm the updated total number of outstanding shares and the impact on existing shareholder dilution.
- Review the Amended Articles of Association (Exhibit 3.1) for any changes to capital structure or governance resulting from the offering.
- Check subsequent filings for the actual use of proceeds as disclosed in the prospectus supplement.